NuVasive price target raised to $22 from $19 at RW Baird Baird raised its price target on NuVasive following solid Q4 results. The firm cited reasons to expect higher revenue growth on better than expected leverage opportunities. Baird likes the risk/reward and maintains its Outperform rating.
On The Fly: Analyst Upgrade Summary Today's noteworthy upgrades include: CyrusOne (CONE) upgraded to Buy from Hold at Stifel... MGIC Investment (MTG) upgraded to Conviction Buy from Buy at Goldman... NuVasive (NUVA) upgraded to Outperform from Market Perform at Wells Fargo... Phillips 66 (PSX) upgraded to Outperform from Neutral at Credit Suisse... Pinnacle Foods (PF) upgraded to Buy from Hold at Deutsche Bank... Rayonier (RYN) upgraded to Outperform from Sector Perform at RBC Capital.. Thoratec (THOR) upgraded to Outperform from Market Perform at Wells Fargo... Volcano (VOLC) upgraded to Outperform from Neutral at Credit Suisse... Progressive Waste (BIN) upgraded to Neutral from Underperform at Macquarie... Clean Harbors (CLH) upgraded to Outperform from Neutral at Wedbush... McGraw Hill Financial (MHFI) upgraded to Buy from Hold at Benchmark Co... Chesapeake (CHK) upgraded to Outperform from Market Perform at Bernstein... American Science & Engineering (ASEI) upgraded to Fair Value from Sell at CRT Capital... Sony (SNE) upgraded to Overweight from Equal Weight at Morgan Stanley.
NuVasive upgraded to Outperform from Market Perform at Wells Fargo Wells Fargo upgraded NuVasive to Outperform after attending last week's North American Spine Society annual meeting. Wells believes the worldwide spine market continues to improve and that NuVasive is well positioned to capitalize on the momentum. The firm raised its price target range for shares to $50-$52 from $43-$44.